Filing Details
- Accession Number:
- 0001193125-23-038538
- Form Type:
- 13G Filing
- Publication Date:
- 2023-02-13 19:00:00
- Filed By:
- MSDC Management
- Company:
- Plx Pharma Inc. (NASDAQ:PLXP)
- Filing Date:
- 2023-02-14
- SEC Url:
- 13G Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| MSD Partners | 0 | 686,685 | 0 | 686,685 | 686,685 | 2.4% |
| MSD Credit Opportunity Master Fund | 0 | 686,685 | 0 | 686,685 | 686,685 | 2.4% |
CUSIP No. 72942A107
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No.1)*
PLX PHARMA INC.
(Name of Issuer)
Common Stock, $.001 par value per share
(Title of Class of Securities)
72942A107
(CUSIP Number)
December 31, 2022
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)
| * | The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. |
The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)
CUSIP No. 72942A107
| 1 | NAMES OF REPORTING PERSONS
MSD Partners, L.P. | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ☐ (b) ☒
| |||||
| 3 | SEC USE ONLY
| |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware | |||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER
-0- | ||||
| 6 | SHARED VOTING POWER
686,685 (1) | |||||
| 7 | SOLE DISPOSITIVE POWER
-0- | |||||
| 8 | SHARED DISPOSITIVE POWER
686,685 (1) | |||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
686,685 (1) | |||||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
☐ | |||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
2.4% (2) | |||||
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
PN | |||||
| (1) | Represents shares of common stock underlying the 2,129 shares of Series B Convertible Preferred Stock beneficially owned by the Reporting Persons. |
| (2) | The percentage used herein and in the rest of this Schedule 13G is calculated based upon 29,137,692 shares as of November 8, 2022 of the Issuers common stock outstanding as reported in the Issuers Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (SEC) on November 10, 2022, and assuming conversion of all of the 2,129 shares of Series B Convertible Preferred Stock beneficially owned by the Reporting Persons. |
CUSIP No. 72942A107
| 1 | NAMES OF REPORTING PERSONS
MSD Credit Opportunity Master Fund, L.P. | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ☐ (b) ☒
| |||||
| 3 | SEC USE ONLY
| |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands | |||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER
-0- | ||||
| 6 | SHARED VOTING POWER
686,685 (1) | |||||
| 7 | SOLE DISPOSITIVE POWER
-0- | |||||
| 8 | SHARED DISPOSITIVE POWER
686,685 (1) | |||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
686,685 (1) | |||||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
☐ | |||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
2.4% (2) | |||||
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
PN | |||||
| (1) | Represents shares of common stock underlying the 2,129 shares of Series B Convertible Preferred Stock beneficially owned by the Reporting Persons. |
| (2) | The percentage used herein and in the rest of this Schedule 13G is calculated based upon 29,137,692 shares as of November 8, 2022 of the Issuers common stock outstanding as reported in the Issuers Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (SEC) on November 10, 2022, and assuming conversion of all of the 2,129 shares of Series B Convertible Preferred Stock beneficially owned by the Reporting Persons. |
CUSIP No. 72942A107
| Item 1(a) | Name of Issuer: |
The name of the issuer is PLx Pharma Inc. (the Company).
| Item 1(b) | Address of Issuers Principal Executive Offices: |
The Companys principal executive office is located at 9 Fishers Lane, Suite E, Sparta, New Jersey, 07871.
| Item 2(a) | Name of Person Filing: |
This Schedule 13G is being jointly filed by and on behalf of each of MSD Partners, L.P. (MSD Partners) and MSD Credit Opportunity Master Fund, L.P. (MSD Credit Opportunity Master Fund). MSD Credit Opportunity Master Fund is the direct owner of the securities covered by this statement.
MSD Partners is the investment manager of, and may be deemed to beneficially own securities beneficially owned by, MSD Credit Opportunity Master Fund. MSD Partners (GP), LLC (MSD GP) is the general partner of, and may be deemed to beneficially own securities beneficially owned by, MSD Partners. Gregg R. Lemkau maintains investment discretion over this investment and therefore may be deemed to beneficially own securities beneficially owned by MSD GP.
The Reporting Persons have entered into a Joint Filing Agreement, dated February 14, 2023, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.
Neither the filing of this statement nor anything herein shall be construed as an admission that any person other than the Reporting Persons is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.
| Item 2(b) | Address of Principal Business Office or, if none, Residence: |
The address of the principal business office of MSD Partners is One Vanderbilt Avenue, 26th Floor, New York, New York 10017.
The address of the principal business office of MSD Credit Opportunity Master Fund is One Vanderbilt Avenue, 26th Floor, New York, New York 10017.
| Item 2(c) | Citizenship: |
MSD Partners is organized as a limited partnership under the laws of the State of Delaware.
MSD Credit Opportunity Master Fund is a limited partnership organized under the laws of the Cayman Islands.
| Item 2(d) | Title of Class of Securities: |
Common Stock, par value $0.001 per share.
| Item 2(e) | CUSIP No.: |
72942A107
| Item 3 | If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
Not applicable.
CUSIP No. 72942A107
| Item 4 | Ownership: |
| A. | MSD Partners, L.P. |
| (a) | Amount beneficially owned: 686,685 |
| (b) | Percent of class: 2.4% |
| (c) | Number of shares as to which such person has: |
| (i) | Sole power to vote or direct the vote: -0- |
| (ii) | Shared power to vote or direct the vote: 686,685 |
| (iii) | Sole power to dispose or direct the disposition: -0- |
| (iv) | Shared power to dispose or direct the disposition: 686,685 |
| B. | MSD Credit Opportunity Master Fund, L.P. |
| (a) | Amount beneficially owned: 686,685 |
| (b) | Percent of class: 2.4% |
| (c) | Number of shares as to which such person has: |
| (i) | Sole power to vote or direct the vote: -0- |
| (ii) | Shared power to vote or direct the vote: 686,685 |
| (iii) | Sole power to dispose or direct the disposition: 0 |
| (iv) | Shared power to dispose or direct the disposition: 686,685 |
| C. | MSD Partners (GP), LLC |
| (a) | Amount beneficially owned: 686,685 |
| (b) | Percent of class: 2.4% |
| (c) | Number of shares as to which such person has: |
| (i) | Sole power to vote or direct the vote: -0- |
| (ii) | Shared power to vote or direct the vote: 686,685 |
CUSIP No. 72942A107
| (iii) | Sole power to dispose or direct the disposition: -0- |
| (iv) | Shared power to dispose or direct the disposition: 686,685 |
| D. | Gregg R. Lemkau |
| (a) | Amount beneficially owned: 686,685 |
| (b) | Percent of class: 2.4% |
| (c) | Number of shares as to which such person has: |
| (i) | Sole power to vote or direct the vote: -0- |
| (ii) | Shared power to vote or direct the vote: 686,685 |
| (iii) | Sole power to dispose or direct the disposition: -0- |
| (iv) | Shared power to dispose or direct the disposition: 686,685 |
| Item 5 | Ownership of Five Percent or Less of a Class: |
If this statement is being filed to report the fact that as of the date hereof each of the Reporting Persons has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.
| Item 6 | Ownership of More Than Five Percent on Behalf of Another Person: |
Not applicable.
| Item 7 | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person: |
Not applicable.
| Item 8 | Identification and Classification of Members of the Group: |
Not applicable.
| Item 9 | Notice of Dissolution of Group: |
Not applicable.
| Item 10 | Certification: |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
CUSIP No. 72942A107
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Schedule 13G is true, complete and correct.
| Date: February 14, 2023 | ||
| MSD Partners, L.P. | ||
| By: | MSD Partners (GP), LLC | |
| Its: | General Partner | |
| By: | /s/ Robert K. Simonds | |
| Robert K. Simonds, Authorized Signatory | ||
| MSD Credit Opportunity Master Fund, L.P. | ||
| By: | MSD Partners, L.P. | |
| Its: | Investment Adviser | |
| By: | MSD Partners (GP), LLC | |
| Its: | General Partner | |
| /s/ Robert K. Simonds | ||
| Robert K. Simonds, Authorized Signatory | ||
CUSIP No. 72942A107
EXHIBIT INDEX
| Exhibit | Description of Exhibit | |
| Exhibit 99.1 | Joint Filing Agreement dated February 14, 2023. | |